Andersen advises Ship2B Ventures on a €14m financing round for Aortyx
Andersen has advised Ship2B Ventures, a venture capital firm that invests in impact startups, on the Series A financing round that has raised €13.8 million for Aortyx, a medical technology scaleup based in Barcelona.
With this financial muscle, Aortyx will conduct the first clinical trials in patients of its bioabsorbable patch that treats aortic tears, a condition that affects more than 50,000 Europeans a year. This device is an alternative to existing treatments that incur high mortality and morbidity rates in the short, medium and long term.
Ship2B Ventures is committed to solutions that, through profound innovation, generate real and lasting transformations in the face of major global challenges. The round in Aortix was led by its investment fund, BSocial Impact, together with Clave Capital, Nara Capital, the EIC fund, the CDTI, business angels and one of the world’s top five manufacturers of aortic devices.
Aortix is a company founded in 2018 by researchers from the IQS School of Engineering and Hospital Clínic de Barcelona. Its goal is to develop a new generation of endovascular devices for the treatment of vascular diseases.
Ricardo Torres, partner in the M&A department, together with Ana Barroso, associate, and Carla Aguilar, lawyer, advised on the transaction.
